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1. Introduction 
Chronic constipation is one of the most common conditions, with prevalence by various 
estimates ranging from 1.9% to 27.2% in the American population (Bharucha et al., 2000; 
Higgins & Johanson, 2004; Shah et al., 2008). Treatment options range from older over-the-
counter laxatives to recently approved prescription drug therapies (Longstreth et al., 2006; 
Motola et al., 2002; Ramkumar & Rao, 2005; Tack & Müller-Lissner, 2009; Tack et al., 2011; 
Tramonte et al., 1997). It has been estimated that 6 million to 8.5 million patients seek 
medical care for constipation each year. Over 70% of these individuals express 
dissatisfaction with prior medications, pointing to the need for new therapies (Johanson & 
Kralstein, 2007). 
Drugs that have been recently approved or which are in late-stage trials for treatment of 
constipation are listed in Table 1. These include prokinetic agents (5-HT4 receptor agonists),  
 
Drug class Agent Mechanism of action Status 
 
5-HT4 receptor agonist Prucalopride Prokinetic: Stimulation of Approved in Europe 
 dnalreztiwS dna sislatsirep cinoloc  
 2 esahP detelpmoC  gartesuleV 
 2 esahP detelpmoC  edirpanoraN 
 
Secretagogue Lubiprostone ClC2 channel and CFTR Approved in US and  
  rof dnalreztiwS rotavitca lennahc  
 c-SBI dna CIC   
  ni detelpmoc 3 esahP tsinoga RCCG editolcaniL 
 eporuE dna SU   
ga RCCG editanacelP onist Phase 2 in US 
 detelpmoc 2 esahP rotibihni TABI 9033A 
  
Absorption inhibitor Na-H exchange RDX-5791 Phase 2 in US 
  rotibihni 
 
Table 1. Drugs recently approved or in late-stage clinical trials for chronic idiopathic 
constipation 
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secretagogues (guanylate cyclase C receptor agonists, bile acid transport inhibitors, Cl 
channel activators), and Na-H exchange inhibitors. Prokinetic agents promote colonic motor 
activity and propulsion, while secretagogues and Na-H exchange inhibitors either induce 
secretion of water and electrolytes or inhibit their absorption, resulting in more water in 
luminal contents. All of these agents appear to accelerate colonic transit time and accentuate 
stool output. There is little known at this point regarding comparative efficacy and safety 
between individual drugs or drug classes. Although speculative, it is likely that different 
drugs and drug classes will be used concomitantly in patients who fail to achieve the 
desired therapeutic response. 
Serotonin (5-hydroxytryptamine, 5-HT) is a critical regulator of gastrointestinal motility, 
sensitivity, and secretion (Gershon, 2004). 5-HT triggers and coordinates intestinal peristalsis 
through 5-HT4 receptors expressed mainly on enteric neurons (Gershon & Tack, 2007). The 
safety of the 5-HT4 subclass has been brought into scrutiny because of the withdrawal of two 
previously marketed drugs, as will be discussed below. The highly selective 5-HT4 agonists 
currently under development are expected to exhibit more favorable safety profiles with low 
potential for cardiovascular side effects (DeMaeyer et al., 2008). 
This review will provide an oversight of drugs that have been recently approved or are 
currently in late-stage clinical development for chronic idiopathic constipation (CIC). We 
will focus on methodologies (endpoints, study populations, biomarkers) that have been 
employed in proof-of-concept (Phase 2) and late-stage confirmatory clinical trials (Phase 3). 
We will discuss specific drug properties (dosing, drug-drug interactions, and specificity) 
that are the expected outcome of these trials. The goal of the clinical development program 
in CIC is to thoroughly document a drug profile with an acceptable balance between 
efficacy and safety. 
The use of opioids and the side effects of opioid use have reached near epidemic 
proportions in the United States. The prevalence of constipation in this population is 
estimated to range between 20% and 70% (Bell et al., 2009; Brown et al., 2006; Kalso et al., 
2004). While there have been considerable efforts directed towards the development of 
drugs for treating opioid-induced constipation, our review will focus on constipation from 
other causes. 
2. Drug properties impacting clinical development  
2.1 Pharmacokinetic and pharmacodynamic profiles  
Compounds currently in clinical development are intended to be used as chronic oral 
therapies rather than periodically as rescue treatment. Therefore, pharmacokinetics of each 
compound after repeated dosing will play an important role in differentiating ease of use 
(i.e., once daily), potential accumulation, drug-drug interaction, etc. Drugs that promote 
more frequent and complete defecation may act locally on the GI mucosa or exert their 
effects systemically. The degree in which systemic exposure drives clinical efficacy varies by 
drug class, expected site of action in GI tract, and pharmacokinetics of each compound. 
High molecular weight (e.g., peptides) ordinarily renders a drug non-absorbable. Some 
constipation drugs have been postulated to exert their effects by local and systemic 
mechanisms simultaneously (Hoffman et al., 2010). 5-HT4 agonists currently under 
development are small molecules that are absorbed and systemically available, while the 
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newer secretagogues, such as linaclotide and plecanatide, are peptides that are unabsorbed 
and systemically inert (Harris & Cromwell, 2007; Shailubhai et al., 2010). The maximal 
tolerated dose (MTD) of a systemically available drug depends on many factors, including 
end-organ toxicities and drug interactions, while the therapeutic limit of non- or minimally 
absorbed drugs mainly reflects GI tolerance. Irrespective of these considerations, all 
compounds for the treatment of constipation possess the inherent potential to produce 
diarrhea when administered at sufficient doses, due presumably to their exaggerated 
pharmacology rather than some off-target activity. Diarrhea led to study discontinuation in 
almost 5% of subjects in recent Phase 3 trials of linaclotide (Lembo et al., 2010a).  
Absence of systemic exposure minimizes but does not eliminate the possibility drug-drug 
interactions or drug toxicity. Drug interactions, for example, could still occur with efflux 
proteins (e.g., p-glycoprotein) at the enterocyte brush border (Huang & Woodcock, 2009). 
A3309, a non-absorbed inhibitor of bile acid transport (IBAT) that blocks bile acid re-
absorption by the terminal ileum (Chey et al., 2011a) could theoretically impair long-term 
fat-soluble vitamin absorption (Vitamin A, E, D) or lead to other nutritional deficiencies. The 
choleretic compound class has also been associated with higher rates of abdominal 
cramping and diarrhea in clinical trials (Odynsi-Shiyanbade et al., 2010). 
There have been few examples of non-GI adverse events using the newer 5-HT4 agonists. As 
will be discussed below, the infrequency of these events probably relates to higher 
specificity for the 5-HT4 receptor than earlier agents. Certain 5-HT4 agonists (prucalopride 
and velusetrag) have been associated with a low but increased incidence of headaches and 
nausea compared with placebo. Although these side effects were reported in smaller 
percentages of patients in clinical trials of naronapride, the relationship between these 
adverse events and degree of CNS penetration is unclear (Palme et al., 2010). These side 
effects have been shown to resolve after the first day of treatment (Camilleri et al., 2008; 
Goldberg et al., 2010).  
Linaclotide is a GCCR agonist and synthetic analog of E. coli STa toxin that stimulates 
intracellular c-GMP activity and active Cl secretion. Linaclotide is released and degraded 
rapidly in the duodenum (Kessler et al., 2008). This being the case, the stool hydrating effect 
of linaclotide must rely on a rapid burst of secretion in the upper intestine. Colonic motor 
dysfunction could potentially blunt or eliminate the subsequent therapeutic responses to 
linaclotide, reflecting the prodigious organ specific capacity for water reabsorption by the 
colon, coupled with prolonged transit (Debongnie & Phillips, 1978). Titration of distal stool 
volume might be difficult to control by a proximally active mechanism, resulting in wider 
swings in fecal output and higher rates of diarrhea-associated adverse events. Consistent 
targeting of specific sites along the length of the GI tract could be difficult with a luminally 
active agent. A 10-fold to 100-fold inter-individual variability in GCC mRNA expression has 
been observed in the human intestine (Bharucha et al., 2010), adding to the challenge of 
proper dosing in individual patients. 
Plecanatide is a synthetic analogue of naturally occurring uroguanylin that mediates basal 
secretion and cell volume in humans (Shailubhai et al., 2010). In contrast to linaclotide, 
which is stabilized by three disulfide bonds that maintain the peptide in a tight 
configuration (Harris & Cromwell, 2007), the molecular structure of plecanatide contains 
only two disulfide bonds (Shailubhai et al., 2010), potentially rendering it less stable at its 
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intestinal site of action. Furthermore, its binding to GCC receptors is pH-dependent. 
Perhaps as a result of these properties, plecanatide manifests three-fold to five-fold lower 
potency compared with linaclotide in human studies on a concentration basis (Lembo et al., 
2010a; Shailubhai et al., 2010). Plecanatide was associated with a lower incidence of diarrhea 
in a preliminary trial of constipated patients, but this could potentially be representative of 
lower rates of intestinal secretion induced by the compound (Shailubhai et al., 2010).  
2.2 Receptor specificity and off-target effects 
5-HT in the GI tract is primarily stored in gut enterochromaffin cells, with a much smaller 
portion in enteric neurons. High selectivity is an important feature of newer 5-HT4 agonists 
like prucalopride, velusetrag, and naronapride. Early 5-HT4 agonists were associated with 
non-specific receptor binding and off-target cardiac findings. Metoclopramide, a mixed 5-
HT4 agonist and D2 antagonist, has been associated with tardive dyskinesia as a result of 
antagonism of striatal dopamine receptors, leading the FDA to issue a black box warning 
restricting recommended use (Metozolv Prescribing Information, 2009). Up to 30% of 
patients using metoclopramide discontinue treatment due to various other CNS side effects 
(Lee and Kuo, 2010).  
Cisapride, a benzamide, was a 5-HT4 agonist that facilitated release of acetylcholine 
throughout the gut. It was used widely for treatment of gastro-esophageal reflux disease, 
gastroparesis and functional dyspepsia (Wiseman & Faulds, 1994). While the efficacy of 
cisapride in upper gastrointestinal tract motility was widely recognized, its effects on 
constipation and lower GI motility have been questioned (Abourmarzouk 2011). The loss of 
effect in the lower GI tract was attributed to concomitant antagonism of the 5-HT3 and 
potentially 5-HT2 receptor, leading to opposing effects on colonic transit and secretion 
(Masaoka & Tack, 2009).  
In 2000, cisapride was withdrawn from the market due to fatal arrhythmias and dose-
dependent QT interval prolongation (Masaoka & Tack, 2009). These events occurred notably 
in patients taking other medications that are known to inhibit the CYP450 3A4 isozyme, e.g., 
erythromycin, fluconazole and amiodarone. Although the basis of cisapride’s 
arrhythmogenic effect was not fully understood, it has been attributed to blockade of hERG 
(human ether-a-go-go) potassium channels, and a resulting delay in cardiac action potential 
repolarization in ventricular muscle and Purkinje fibers, and unrelated to its 5-HT4 agonist 
properties (Tonini et al., 1999).  
Tegaserod, a 5-HT4 receptor partial agonist of aminoguanidine indole class, was approved 
in the United States for the treatment of chronic constipation and irritable bowel syndrome 
with constipation (Al-Judaibi et al., 2010). Although several studies (Prather et al., 2000; 
Foxx-Orenstein et al., 2005) demonstrated prokinetic action of tegaserod in both upper and 
lower GI tract, data regarding improvement of gastric emptying in humans are inconsistent 
(Talley et al., 2006; Degen et al., 2001, 2005). Tegaserod was withdrawn from the market in 
2007 because of a reported numerical imbalance in the number of patients with 
cardiovascular ischemic adverse events in trials for patients who received tegaserod 
compared with those on placebo (Pasricha, 2007). Subsequent epidemiologic studies 
(Anderson et al., 2009; Loughlin et al., 2010) failed to confirm a reported large event 
differential for tegaserod that was noted incidentally in this clinical trial database. 
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Tegaserod is now recognized to have significant affinity for non-5-HT4 receptors, including 
the 5-HT1B, 5-HT1D and 5-HT2B subtypes (Borman et al., 2002; DeMaeyer et al., 2008). The 
effects of tegaserod on 5-HT1 receptors present on blood vessels and platelet aggregation 
have been implicated as a mechanism accountable for ischemic changes (Chan et al., 2009; 
DeMaeyer et al., 2008; Serebruany et al., 2010). Moreover, the potent 5-HT2B antagonism of 
tegaserod has been postulated to counteract its 5-HT4 prokinetic effect (Borman et al., 2002). 
Low oral bioavailability (10%) may also have reduced the efficacy of the compound 
(Johanson et al., 2004; Kamm et al., 2005). 
3. First-in-human trials  
3.1 Exposure-response relationship and dose-selection 
Single and repeat dose studies are routinely conducted first in healthy volunteers with 
normal bowel function. The benefit of this approach is the ability to establish preliminary 
pharmacokinetics and safety profiles in subjects without significant pre-existing conditions. 
These compounds induce defecatory changes in healthy volunteers, such as increasing 
bowel movement frequency. However, the doses responsible for these changes in healthy 
volunteers appear to be higher than the therapeutic dose in chronic constipation patients. GI 
pharmacodynamic effects in healthy volunteers are dose-dependent and the GI adverse 
events (i.e., diarrhea) tend to subside after the first dose. In general, there is very limited 
information on the pharmacokinetic-pharmacodynamic relationship for drugs for this 
indication. These first-in-man studies are typically followed by pilot dose-ranging safety 
and efficacy trials in the affected population. Study phases were compressed in the 
plecanatide program (Shailubhai et al., 2010), which chose to progress to initial repeat-dose 
studies directly in constipated patients rather than after single-dose studies in normal 
volunteers. This accelerated approach would seem justified due to the absence of systemic 
bioavailability and dose accumulation.  
In addition to the typical Phase 1 safety studies, gut transit time measurements have been 
employed to test the prokinetic effects of these compounds in the upper and lower GI tract. 
These studies have utilized scintigraphic techniques in patients and healthy volunteers 
(Degen et al., 2001, 2005; Camilleri et al., 2007; Manini et al., 2010; Talley et al., 2006). 
Endpoints have included colonic transit time (GC24), ascending colon emptying (ACE) T1/2, 
gastric emptying (GE) time and colonic filling at 6 hours (CF6). These endpoints have served 
as biomarkers for drug effect in the upper and lower GI tract and have guided subsequent 
indications. Pharmacodynamic endpoints such as scintigraphic transit time are easier to 
achieve and require fewer subjects than those than those employed in registration trials. 
This approach minimizes study timeline and cost. It is worth noting that subsequent 
therapeutic doses for chronic constipation also tend to be lower than the doses needed to 
demonstrate pharmacodynamic effect in transit studies (Goldberg et al., 2010; Manini et al., 
2010).  
Dose proportional effects on stool frequency, stool consistency, and other symptoms 
associated with constipation are ordinarily observed with compounds in both the 5-HT4 and 
secretagogue drug classes. With the possible exception of plecanatide, the incidence of 
diarrhea rises with use of these agents at higher doses. Drugs such as prucalopride, velusetrag, 
linaclotide, plecanotide, A3309, and RDX-5791 exhibit prolonged pharmacokinetic exposures 
and/or pharmacodynamic effects and offer the advantage of once daily dosing. 
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4. Late-stage clinical trials  
4.1 Study population  
Despite treatment dissatisfaction with OTC medications (Johanson & Kralstein, 2007), there 
have been no prospective definitions of treatment failure with prior treatment in clinical 
trials. To date, treatment failure has not been an entry requirement into any late-stage 
constipation trial. In one of the three pivotal trials that formed the basis of the approval of 
prucalopride for CIC in Europe in 2009, 87% of subjects with constipation reported 
dissatisfaction with prior laxative regimens (Tack et al., 2009). Other than this one trial, the 
concept of treatment refractoriness has not been adequately addressed in registrational 
trials, which regulatory authorities use to develop label claims. It will be important to make 
this distinction prospectively if the role of newer medications in the constipation treatment 
paradigm is to be fully understood. Other study population considerations are outlined in 
Table 2. 
Rome III Criteria (Modified) 
- ≤ 3 SBM per week 
- One or more of the following symptoms occurring on ≥ 25% of BM for at least 12 
weeks during the preceding 12 months 
 Straining during bowel movements 
 Lumpy or hard stools  
 Sensation of incomplete evacuation 
Treatment dissatisfaction or failure 
Gender 
Elderly population (over 65 years of age) 
Pelvic floor dyssynergia 
Renal or hepatic impairment 
 
Exploratory: 
Transit time measurements 
Table 2. Key Inclusion/Exclusion Criteria and Considerations in Constipation Trials 
It is important to demonstrate safety and efficacy in most patients who are most often 
affected. In general, CIC is more common in women (Chuong et al., 2007), and not 
surprisingly, the majority of subjects who have participated in clinical trials have been 
women. The label claim of prucalopride was restricted to women because the enrollment of 
low number of male subjects in clinical trials precluded proof of efficacy in men. Although 
the data are very limited, the effective dose in males may also be higher than females 
(European Medicines Agency, 2009). 
Constipation affects up to 50% of elderly individuals and is especially prevalent in nursing 
home residents (Camilleri et al., 2009; Chuong et al., 2007; Müller-Lissner et al., 2010). 
However, pharmacokinetics, the safety and tolerability profile and clinical efficacy in elderly 
patients may be different than in the younger population. The elderly population is 
routinely restricted in earlier pharmaceutical development due to safety considerations. The 
efficacy of prucalopride in the elderly population was demonstrated in a late-stage, 
multicenter trial of 300 elderly patients (Müller-Lissner et al., 2010). A subsequent safety 
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trial was conducted in frail elderly patients residing in a nursing facility (Camilleri et al., 
2009). Dosing should take diminishing renal function into the consideration if the drug is 
eliminated through the kidney. The effect of age on the pharmacokinetics of prucalopride 
was studied in an open, parallel-group trial in 12 healthy elderly (age range 65 to 81 years) 
and 12 young subjects (European Medicines Agency, 2009). Peak plasma concentrations and 
AUC of prucalopride were 26% to 28% higher in elderly subjects compared with young 
adults, due to diminishing renal function with age.  
Patients participating in late-stage constipation trials should meet established definitions for 
chronic idiopathic constipation. The Rome II criteria for CIC were published in 1999 
(Thompson et al., 1999), and followed by the Rome III criteria in 2006 (Longstreth et al., 
2006). Modifications of these criteria have become working standards for inclusion and 
exclusion in constipation trials. The Rome criteria provide for a history of ≤ 3 SBMs per 
week and having one or more of the following symptoms for at least 12 weeks during the 12 
months preceding the study: (1) straining during ≥ 25% of BMs; (2) lumpy or hard stools 
during ≥ 25% of BMs; or (3) sensation of incomplete evacuation during ≥ 25% of BMs.  
The unmodified Rome III criteria for CIC include the sensation of anorectal obstruction or 
need for manual maneuvers to facilitate defecation (e.g., digital evacuation, support of the 
pelvic floor). Approximately 10% of subjects with CIC have functional outlet obstruction 
associated with pelvic floor dysfunction (Lembo & Camilleri, 2003). Formal radiographic or 
manometric testing is required to establish the diagnosis. These patients may be less 
responsive to pharmaceutical approaches than other patients, and are more appropriately 
treated with biofeedback or surgical methods (Lembo & Camilleri, 2003; Locke et al., 2000). 
Study protocols have typically tried to exclude patients with a history of dyssynergic 
defecation or in whom the history and physical examination was felt to indicate the 
presence of this type of constipation (Johanson et al., 2004; Lembo et al., 2010b).  
To confirm the diagnosis of CIC, patients typically undergo a two-week baseline screening 
period during which time they must report an average of ≤ 3 CSBMs and ≤ 6 SBMs per week 
for inclusion. The patient responses are generally captured via an electronic diary or 
interactive voice response system. Use of a laxative, enema, and/or suppository usage for 
two or more days, or the report of any watery stools (Type 7) or > 1 loose (mushy) stools 
(Type 6) on the Bristol Stool Form Scale [BSFS] (Lewis & Heaton, 1997) would exclude a 
patient from participation. 
Although constipation is associated with slower colonic transit, only a small portion of 
patients with CIC have abnormally slow transit times on formal testing (Lembo & Camilleri, 
2003). Although transit time measurements may be a useful gauge for the effectiveness of an 
investigational agent, particularly in the early stages of clinical development, there would 
appear to be insufficient rationale to qualify patients for late-stage trials based on these 
transit time measurements. 
4.2 Endpoints 
Efficacy in constipation trials should signify improvement in constipation-associated 
symptoms. Endpoints in constipation trials are therefore patient-reported. Regulatory 
standards for tools to measure symptom-based endpoints in the United States is built on the 
FDA Guidance for Patient Reported Outcomes, issued in draft form in February 2006 and 
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finalized in December 2009 (US Food and Drug Administration, 2009). Primary efficacy 
endpoints in late-stage constipation trials typically embody increases in the number of 
bowel movements (BM) per day, either improvement in spontaneous bowel movements 
(SBM) or complete spontaneous bowel movements (CSBM) (Table 3). A BM is deemed an 
SBM if no laxative, enema, or suppository was taken in the preceding 24 hours, and a CSBM 
if the patient indicated that the SBM is associated with a sensation of complete bowel 
emptying. Until there is a well-validated patient reported outcome tool the FDA accepts, 
PRO development will need to be considered in parallel with the clinical development 
program. In addition, translation and validation of these tools in different languages will 
also be essential for clinical development plans that expand beyond English speaking 
populations.  
 
 tnemerusaeM tnemurtsnI tnempoleveD fo esahP   
 
First-in-man 
 retnec cirtemoeG TT noloc ro tug elohW yhpargitnicS 
 Stool consistency BSFS  7-point ordinal scale    
 
Early phase (pilot studies) 
garevA  yraid yliaD MBS e change from baseline 
garevA  yraid yliaD MBSC e change from baseline  
 
Late-phase 
  Primary endpoint: 
Responder definition CSBM Daily diary  Categorical variables based 
− Achieving of ≥ 3 CSBM/week     on MID 
− Increase of ≥ 1 CSBM/week    
         (either co-primary or key secondary endpoint)     
  Secondary or exploratory endpoints 
−  elacs lanidro tniop-7 SFSB ycnetsisnoc lootS
− Abdominal pain or discomfort Severity score 11-point ordinal severity scale 
−  elacs ytireves lanidro tniop-5 erocs ytireveS gniniartS
−  elacs ytireves lanidro tniop-5 erocs ytireveS gnitaolB
−  naem ni egnahC  snoitacidem eucser fo esU
−  serocs niamod/ latoT tnemurtsni etisopmoC MYS-CAP
−  serocs niamod/ latoT tnemurtsni etisopmoC LoQ-CAP
−    stniopdne labolG
 Constipation severity Severity score 5-point ordinal severity scale 
 Global relief of constipation  Numerical rating scale 7-point balanced scale 
 Treatment satisfaction Numerical rating scale 5-point ordinal scale 
 Adequate relief  Binary question Binary (yes/no)  
 
Table 3. Endpoints in Clinical Trials in Constipation. Abbreviations:  BSFS, Bristol Stool 
Form Scale; TT, transit time; MID, minimally important difference; CSBM, complete 
spontaneous bowel movement; SBM, spontaneous bowel movement 
The conceptual framework of constipation treatment response embodies symptoms 
considered important to the patient. These typically include stool consistency, straining, 
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abdominal pain, bloating, and feeling of bowel emptying. Stool consistency is typically 
measured on the Bristol Stool Form Scale (BSFS). The constipation symptom roster is usually 
elicited in focus groups of individuals suffering from constipation. Patient responses are 
then structured into questionnaires using psychometric methods described in the guidance. 
These symptoms comprise primary and secondary endpoints that form the basis of label 
claims in the United States.  
Earlier stage trials in constipation typically utilize continuous variables, such as mean 
change in SBM and/or CSBM from baseline across patients groups, for primary efficacy 
endpoints. These endpoints are easier to power and therefore engender lower sample sizes. 
Lubiprostone was approved in the US on the basis of trials that employed changes in SBM 
(Barisch et al., 2010; Johanson et al., 2008). However, the recent guidance makes clear the 
need for responder definitions in late-stage clinical trials (US Food and Drug 
Administration, 2009). 
Responder definitions should be predicated on subjects achieving minimally important 
differences (MID) (US Food and Drug Administration, 2009). These differences are derived 
from factor analyses of clinical data in Phase 2 trials. MIDs are typically determined by 
comparing symptomatic improvement to global improvement questions. The primary 
efficacy endpoint in the prucalopride Phase 3 programs utilized the responder definition of 
≥ 3 CSBM per week (Camilleri et al., 2008; Quigley et al., 2009; Tack et al., 2009), with the key 
secondary efficacy endpoint being the proportion of subjects achieving an increase of ≥ 1 
CSBM per week. Three CSBM per week, i.e., approximately one BM every other day, 
represents normalization of bowel function in many individuals (Drossman et al., 1982), and 
therefore has clinical meaningfulness. The linaclotide Phase 3 program provided for co-
primary endpoints that included achieving both ≥ 3 CSBM and improvement of ≥ 1 
CSBM/week (Lembo et al., 2010a). The achievement of ≥ 3 CSBM per week is a more 
stringent and clinically more relevant endpoint than improvement of ≥ 1 CSBM, and efficacy 
responses on this co-primary endpoint predominantly reflect the subject’s response on the 
first co-primary. It should also be pointed out that CSBM is a more stringent outcome than 
SBM, and that while endpoints predicated on CSBM may have lower response rates than 
SBM, the drudging of placebo performance typically results in improved study power, 
lower sample sizes, and higher chances of trial success.  
Drugs have typically achieved responses in the 18% to 29% range on these CSBM-based 
responder definitions compared with 5% to 15% placebo response in Phase 3 CIC trials. This 
compares to treatment responses of 30% to 40% using SBM-based definitions, but with 
higher placebo responses and overall lower levels of statistical significance (Camilleri et al, 
2008; Lembo et al, 2010a; Quigley et al, 2009; Tack et al, 2009). The observation that only a 
quarter of patients normalize bowel function with monotherapy-based trials suggests that 
the majority of patients will require combination therapy with these agents in the clinic.  
Additional efficacy parameters in constipation trials have included the PAC-SYM (Frank et 
al., 1999), a composite index of constipation-associated symptoms, and PAC-QOL (Marquis 
et al., 2005), a health-related quality of life instrument, neither of which are recognized by 
the FDA as acceptable endpoints for clinical trials in the United States. Use of rescue 
medications and time to first bowel movement have also served as secondary or exploratory 
endpoints in selected trials. Sponsors have typically included global endpoints such as 
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constipation severity and adequate relief as secondary or exploratory endpoints (Lembo et 
al., 2010a), and the FDA supports use of these outcomes other than for primary efficacy 
endpoints (US Food and Drug Administration, 2009). 
4.3 Drug safety  
Safety concerns are tantamount in drug development for constipation, which is viewed by 
both clinicians and regulators a non-lifethreatening condition rather than a disease. The 
tolerance for safety concerns in the treatment of constipation is understandably low. Safety 
exposure databases should be expected at a minimum to follow ICH Guidelines for chronic 
disease and include 300-600 six-month exposures and 100 twelve-month exposures (US 
Food and Drug Administration, 1995). Higher standards may be set by regulatory agencies 
in the future, and the requirement for risk management programs could be imposed on 
drugs seeking approval in the US (US Food and Drug Administration, 2005). 
Pharmacovigilence post-approval has become standard industry practice. When safety is a 
concern, it is important that drug development identify a minimal effective dose and 
provide guidance to clinicians on how dosing should be escalated from that point forward. 
The burden of safety is likely to be reduced for drugs that are locally active compared with 
those that are systemically available, meaning lower requirements for pre-approval 
exposures and lower post-approval safety commitments. The GI tract is ideally suited for 
local or topical exposure by oral or rectal routes of administration. 
Potential for QT interval prolongation and drug-drug interactions that potentiate this effect 
must be identified early in the development program. QT interval prolongation led to the 
market withdrawal of cisapride in 2000 (Masaoka & Tack, 2009). Tegaserod was associated 
with a higher incidence of cardiac ischemic events and withdrawn from the market in 2007 
(Pasricha, 2007). This concern has shadowed development with all subsequent 5-HT4 
agonists, although current data suggest that QT prolongation and cardiac ischemia may 
have been due to off-target effects on other receptors or 5-HT receptor subclasses (Chan et 
al., 2009; DeMaeyer et al., 2008; Serebruany et al., 2010; Tonini et al., 1999). To date, no such 
events have been observed with prucalopride or any of the current 5-HT4 development 
programs.  
4.4 Biomarkers  
A biomarker is a measureable physical, functional, or biochemical surrogate for a 
physiological or disease process that has diagnostic and/or prognostic utility (US Food and 
Drug Administration, 2010a). For many diseases, there is no good way to document the 
course of a disease or the response to treatment. A biomarker may represent the features of a 
biologic processes or a response to a therapeutic intervention and reduce the expense and 
duration of clinical trials. Changes in biomarkers following treatment may reduce 
uncertainty in drug development by predicting drug performance, identifying safety 
problems, or revealing pharmacological activity or other benefit from treatment. The 
European Medicines Agency has also issued guidance for biomarker development in the 
European Union (European Medicines Agency, 2008). 
Radio-opaque markers have been used to assess colonic transit, but recent studies have 
demonstrated scintigraphic imaging to be a more precise tool for drug development in 
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constipation (Camilleri, 2010; Rao S.S. et al., 2011). Scintigraphic transit time fulfills all 
regulatory criteria for a disease biomarker: known performance characteristics, reproducible 
and accurate data over a range of conditions, and evidence of linkage to biological processes 
and clinical endpoints. Changes in colonic transit by scintigraphic technique have generally 
predicted the responses to treatment across a variety of compounds (Camilleri, 2010). This 
may prove to be a biomarker in new drug applications in colonic motility disorders. As 
noted previously, these transit time measurements define transit time abnormalities in only 
a minority of patients and are therefore of no specific utility towards defining subjects who 
enter late-stage clinical trials (Lembo & Camilleri, 2003). Stool frequency correlates poorly 
with colonic transit, but there appears to be good correlation between gut transit and stool 
consistency (O’Donnell, Virgie & Heaton, 1990). These markers are generally well accepted 
and are useful for predicting dose range in subsequent efficacy studies. 
5. Clinical trials of approved drugs or drugs in development  
5.1 5-HT4 receptor agonists  
5.1.1 Prucalopride 
Prucalopride (Resolor®) is a benzofuran carboxamide that is structurally distinct from 
cisapride and tegaserod. Prucalopride exhibits a more than 2-log scale greater selectivity for 
5-HT4 compared with other receptors (DeMaeyer et al., 2008). This selectivity offers promise 
for greater efficacy and safety. The 2 mg once daily dose was approved in Europe in 2009 for 
the treatment of chronic constipation in women who fail to respond to laxatives. Due to the 
pharmacokinetic considerations described above, it is recommended that the drug be 
initiated at 1 mg in elderly patients and increased to 2 mg as needed (European Medicines 
Agency, 2009). 
In pharmacodynamic studies, prucalopride dose-dependently enhanced colonic transit both 
in healthy controls and in patients with chronic constipation. In patients with chronic 
constipation, prucalopride 2 mg and 4 mg were significantly more effective than placebo in 
decreasing GI and colonic transit time. This was also reflected in increased stool frequency 
and looser stool consistency (Bouras et al., 1999, 2001; Sloots et al., 2002). Response in 
patients with constipation was dose-dependent and effective dosage was generally achieved 
with 2 mg once daily, although some studies reported significant beneficial effects on 1 mg 
(Emmanuel et al., 2002; Sloots et al., 2002).  
A total of 2717 patients with chronic constipation were treated in placebo-controlled, 
double-blind, Phase 2 and Phase 3 trials (Miner et al., 1999; Emmanuel et al., 2002; Coremans 
et al., 2003; Camilleri et al., 2008; Quigley et al., 2009; Tack et al., 2009; Müeller-Lissner et al., 
2009). Doses of prucalopride ranged from 0.5 to 4 mg per day. Two of these trials recruited 
patients who were either resistant to, or dissatisfied with laxatives (Coremans et al., 2003, 
Tack et al., 2009), one of these being pivotal (Tack et al., 2009), and one trial involved 
patients aged over 65 years (Müeller-Lissner et al., 2009).  
In the Phase 3 program that served as the basis of approval of prucalopride in Europe, three 
identically designed, multicenter, pivotal trials were conducted (Camilleri et al., 2008; 
Quigley et al., 2009; Tack et al., 2009). More than 85% of the subjects in these trials were 
women. Patients were included based on the criteria of two or fewer SBMs per week in the 
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previous 6 months and very hard or hard stools and/or a sensation of incomplete evacuation 
and/or straining during defecation for at least a quarter of the stools. The primary parameter 
was the proportion (%) of patients with an average of 3 or more spontaneous, complete bowel 
movements per week (responders, ≥ 3 CSBM/week). The main secondary endpoint was the 
proportion of patients with an average increase of ≥ 1 CSBM per week from run-in. The key 
time-point was assessed at Week 12. Treatment with prucalopride 2 mg and 4 mg once daily 
resulted in an average of three spontaneous, complete bowel movements (CSBM) per week in 
19.5% to 28.5% of subjects treated with prucalopride vs. 9.6% to 13.6% receiving placebo. 
Significant changes were also seen in the main secondary endpoint.  
Clinically relevant improvement in constipation-associated symptoms and quality of life 
were observed using the PAC-SYM and PAC-QOL questionnaires in these pivotal trials. 
Nearly 2600 patients were treated with prucalopride in open, long-term studies. 1490 of 
these subjects received treatment for at least 6 months and 869 received at least 1 year of 
treatment. The effects of the 2 mg and 4 mg doses of prucalopride were similar, and both 
were determined to be safe and well tolerated.  
Only one cardiovascular event was reported, an episode of supraventricular tachycardia, 
and extensive cardiovascular safety assessments demonstrated no signals of arrhythmogenic 
potential (Camilleri et al., 2009). The incidence of serious adverse events was similar to 
placebo. Headache, nausea, and diarrhea were reported more often in subjects receiving 
prucalopride, but these adverse events were mainly driven by the occurrence on Day 1 of 
treatment. It was postulated that this represented a transient effect of 5-HT4 agonists that 
penetrate the CNS. However, the relationship between these adverse events and the degree 
of CNS penetration is inconsistent across this class of compounds. 
Data from a series of thorough QT studies appear to show that the influence, if any, of 
prucalopride on QT interval and other ECG variables is negligible. The number of 
cardiovascular ischemic-related events was low and comparable between prucalopride 
groups and placebo (0.1%). Clinical trials with prucalopride were temporarily suspended in 
1999 following positive carcinogenicity studies in rodents; however, these findings were 
deemed to be rodent-specific and were not thought on regulatory review to apply to 
humans (European Medicines Agency, 2009).  
5.1.2 Velusetrag 
Velusetrag (TD-5108) is a high-affinity and selective 5-HT4 receptor agonist with high 
intrinsic activity at the human 5-HT4 receptor. Unlike tegaserod, velusetrag has no 
appreciable affinity for 5-HT1D, 5-HT2A, or 5-HT2B receptors (Beattie et al., 2004; Smith et al., 
2007). In contrast to cisapride, velusetrag has no significant affinity for the human ether-a-
go-go-related gene potassium channel (Smith et al., 2008). In animal models, velusetrag 
demonstrated gastrointestinal activity in the digestive tract. To date, no significant effects of 
velusetrag on blood pressure, heart rate or electrocardiogram have been noted in animals or 
humans at clinically relevant doses, nor does velusetrag have any contractile activity in 
porcine- or canine-isolated coronary arteries (Beattie et al. 2007).  
A dose-response transit study showed that velusetrag administration was associated with 
acceleration of colonic and orocecal transit after single dose administration to healthy 
subjects with substantive and significant effects on gastric and colonic transit were observed 
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with multiple dosing (Manini et al., 2010). In an evaluation of patients with chronic 
constipation and matched healthy control subjects, velusetrag pharmacokinetics and effects 
on laxation and bowel function were similar in chronic constipation and health. 
Bioavailability of velusetrag from a single, orally administrated dose was good, and the 
elimination half-life in both populations was consistent with once daily administration 
(Goldberg, Wong, & Ganju 2007; Wong S.L. et al., 2007). 
A Phase 2, double-blind, placebo-controlled, randomized, parallel-group, multicenter trial 
included 401 subjects with chronic idiopathic constipation (< 3 SBM per week) randomized 
to velusetrag 15 mg, 30 mg, 50 mg or placebo po QD for 4 weeks (Goldberg et al, 2010). The 
study population was 92% female. Patients receiving velusetrag achieved statistically 
significant and clinically meaningful increases in SBM and CSBM relative to placebo at all 
doses. There were no differences in changes in SBM and CSBM rates between doses. Median 
times with first SBM were 21, 25 and 18 hours, respectively, compared to 47 hours for 
placebo (p < 0.0001 for all treatments). Use of velusetrag was significantly associated with a 
relief of straining and bloating, a reduced need for a rescue laxative, and normalization of 
stool consistency. 
The most common adverse events in patients were those frequently associated with 5-HT4 
agents such as prucalopride and included diarrhea, headache, and nausea. These adverse 
events were dose-related, occurred during the initial days of dosing, and were of mild to 
moderate intensity. A total of 19 patients discontinued because of adverse events, with the 
majority occurring in the 50 mg velusetrag group. No clinically relevant changes in 
hematology, biochemistry, urinalysis, vital signs and ECG parameters were observed in any 
group. 
5.1.3 Naronapride 
Naronapride (ATI-7505) is a 5-HT4 receptor agonist belonging to the benzamide series of 
similar compounds (Camilleri et al, 2007). The design of naronapride was based on the 
prototypical benzamide agent, cisapride. Unlike cisapride, naronapride was designed to be 
devoid of other 5-HT receptor activities and to have negligible inhibitory activity at the 
hERG channel, with an affinity ratio between IKr and 5-HT4 receptors of at least 1000- fold. In 
addition, the compound was to have low potential for drug–drug interactions. Unlike 
prucalopride and velusetrag, naronapride does not exhibit CNS penetration, which may 
lead to a lower incidence of side effects  (Aryx Corporation, 2008). However, other 5-HT4 
agonist with limited CNS penetration (i.e., tegaserod) did show comparable rate of adverse 
events to prucalopride and velusetrag.  
A randomized, parallel-group, double-blind, placebo-controlled study evaluated effects of 
9-day treatment with naronapride (3, 10 or 20 mg TID) on scintigraphic GI and colonic 
transit in healthy volunteers (12 per group) (Camilleri et al., 2007). Primary endpoints were 
gastric-emptying (GE) T1/2, colonic geometric centre (GC) at 24 h and ascending colon (AC) 
emptying T1/2. Naronapride increased colonic transit with greatest effect vs. placebo 
observed at 10 mg TID. The effect on transit was associated with looser stool consistency. 
A randomized, multinational, multicenter, double-blind, placebo-controlled, dose-ranging 
trial was performed in patients with CIC (Palme et al., 2010). Patients were randomized to 
naronapride 20 mg, 40 mg, 80 mg or 120 mg or placebo BID orally for four weeks. Although 
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400 subjects were planned in the original study design, the study was terminated early due 
to business reasons, and only 214 patients were randomized. The primary outcome was total 
number of SBMs during Week 1 compared with placebo. Treatment response, a secondary 
endpoint, was defined as the proportion of subjects achieving ≥ 3 CSBM/wk or ≥ 3 
SBMs/wk on each of the four weeks in the absence of rescue medications. Despite the 
reduction from the intended original sample size, all doses of naronapride still met the 
primary endpoint, and median time to first SBM was reduced in all active treatment groups. 
SBM response was achieved by 51.2% of subjects treated with naronapride 80 mg vs. 24.4% 
receiving placebo, while CSBM response was achieved by 26.8% of these subjects vs. 4.9% 
receiving placebo. Adverse event frequency, including headache, diarrhea, nausea and 
vomiting, was similar to placebo in all ATI-7505 dose groups except the 120 mg BID group, 
where abdominal pain and headache were more frequently reported.  
5.2 Colonic secretagogues  
5.2.1 Lubiprostone 
Lubiprostone is a poorly absorbed lipophylic prostanoid component that is thought to 
stimulate colonic water and electrolyte secretion through the activation of type-2 chloride 
channels on enterocytes from the luminal side (Lacy & Levy, 2007). There is also evidence 
that the Cl secretion induced by lubiprostone may be mediated by CFTR channels (Bijvelds 
et al., 2009). Lubiprostone dose-dependently enhances colonic transit, and this was 
hypothesized to be an indirect consequence of increased colonic water content (Camilleri et 
al., 2006).  
In two Phase 3 studies of 4 weeks duration, lubiprostone 24 mg BID significantly enhanced 
SBM frequency (5.69 and 5.89 spontaneous bowel movements per week with lubiprostone 
vs. 3.46 and 3.99 with placebo, p < 0.0001) and relieved other constipation-related symptoms 
compared with placebo (Barish et al., 2010; Johanson et al., 2008). The incidence of nausea in 
patients receiving the approved dose of lubiprostone for chronic idiopathic constipation was 
approximately 29% in clinical trials, and resulted in 9% of patients discontinuing in these 
studies (Lacy & Chey, 2009; Sucampo Pharmaceuticals, 2009). The prevalence of nausea is 
increased with higher dose and could be mediated by an adverse prostaglandin-like effect 
on gastric motility (Lacy & Levy, 2007). Although the systemic availability of lubiprostone is 
reportedly low (Lacy & Levy, 2007), this side effect could potentially reflect systemic 
absorption post oral administration. 
Lubiprostone was approved by the US FDA in 2006 for the treatment of chronic idiopathic 
constipation (24 mg BID) and for the treatment of female IBS patients with constipation (8 
mg BID) (Drossman et al, 2009) in 2008 but, apart from Switzerland, has not been approved 
in Europe at this time.  
5.2.2 Linaclotide 
Linaclotide is a 14-amino acid peptide analog of E. coli STa enterotoxin that acts as an 
agonist at guanylate cyclase-C (GCC) receptor to induce cyclic GMP production and 
intestinal chloride and fluid secretion (Bharucha, Scott & Waldman, 2010). The drug is non-
absorbed and exerts local effects on the enterocyte at the level of the gut lumen. In a 
mechanistic study, linaclotide enhanced colonic transit in IBS with constipation (Andresen 
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et al., 2007). It dose-dependently increased SBM and CSBM frequency, loosened stool 
consistency, and improved other symptoms of constipation over four weeks (Lembo et al., 
2010b).  
Favorable outcomes were recently achieved in two large Phase 3 studies, each involving 
more than 600 subjects, and 12 weeks of treatment. Trial design considered the Food and 
Drug Administration’s recent recommendations to transition from global (e.g., overall relief) 
to symptom-based primary endpoints (US Food and Drug Administration, 2010b). Subjects 
were randomized to placebo and 133 or 266 mg of linaclotide (Lembo et al, 2010a). The 
primary endpoint was based on a responder analysis of subjects achieving both ≥ 3 CSBM 
and an increase of ≥1 CSBM per week. In both trials, significantly higher percentages of 
patients met the primary endpoint with linaclotide 133 mg (respectively 16% and 21.2%) and 
266 mg (respectively 21.4% and 19.3%) compared with placebo (respectively 6% and 3.3%, 
all p-values < 0.001). The onset of efficacy occurred in the first week and was maintained for 
12 weeks. Symptoms of abdominal discomfort, bloating and straining were also significantly 
improved. There was also improvement in health-related quality of life, and constipation 
severity. Linaclotide is also under evaluation for IBS with constipation (Johnston et al, 2010), 
and an application for marketing approval of linaclotide in the US and Europe for both 
indications is expected in the near future.  
5.2.3 Plecanatide 
Plecanatide (SP-304) is an oral peptide analogue of uroguanylin, a natriuretic hormone that 
regulates ion and fluid transport in the GI tract. T84 cell assays have demonstrated that 
plecanatide has an 8-fold higher binding affinity to GC-C receptors than uroguanylin. In a 
double-blind, placebo-controlled, randomized, single ascending dose study conducted in 
healthy volunteers, plecanatide appeared to demonstrate an increase in post-dose stool 
consistency score versus placebo (Shailubhai et al., 2008). The drug was well-tolerated at all 
doses with no systemic exposure. A subsequent Phase 2a trial in constipated subjects 
studied doses between 0.3 and 9 mg once daily for 14 days (Shailubhai et al., 2010). Dose 
proportionate reduction in time to first BM, SBM, CSBM, and stool consistency, and 
improvement of straining were observed up to 1.0 mg, subsequent to which no additional 
effects were noted. There was no detectable absorption of plecanatide at any dose, and 
minimal adverse events were observed. There were no reports of diarrhea in any dose 
groups, although the effects of plecanatide on SBM frequency and stool consistency were 
less pronounced than in earlier linaclotide trials. 
5.2.4 A3309 
A3309 is a potent and selective inhibitor of the ileal bile acid transporter (IBAT) with 
minimal systemic exposure. It dose-dependently inhibits the reabsorption of bile acids (BA). 
This results in an increased concentration of bile acids in the colon, which, in turn, increase 
fluid secretion and colonic motility. 
In a randomized, double-blind, dose-escalating study, 30 patients were administered A3309 
(0.1, 0.3, 1, 3 or 10 mg once daily) or placebo for 14 days (Simrén et al., 2011). Colonic transit 
was measured using radio-opaque markers and fluoroscopy at baseline and at Day 14. 
Bowel movements (BMs), stool consistency (Bristol Stool Form Scale) and GI symptoms 
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were recorded daily. Hepatic BA synthesis was estimated by measurement of 7α-hydroxy-4-
cholesten-3-one (C4) in peripheral blood. Dose-dependent inhibition of bile acid desorption 
and acceleration of colonic transit time and SBMs were noted.  
In a follow-up trial, 36 female patients were randomized to placebo, 15 mg A3309, or 20 mg 
A3309 administered orally once daily for 14 consecutive days (Wong B.S. et al., 2011). Whole 
gastrointestinal and colonic transit, stool consistency, constipation symptoms, serum 7αC4, 
and fasting serum total and LDL cholesterol (surrogates of inhibition of BA absorption) 
were measured. Colonic transit at 48h was significantly accelerated with both A3309 
dosages. Significantly looser stool consistency, lower constipation severity and straining, 
and improved ease of stool passage were noted with both A3309 dosages. A3309 treatment 
significantly and reversibly increased fasting 7αC4. The most common side effect was lower 
abdominal pain or cramping.  
Positive results from a larger, proof-of-concept trial have recently been published (Chey et 
al., 2011a). 190 patients with severe constipation were treated with 5 mg, 10 mg, or 15 mg 
A3309 or placebo for 8 weeks. Subjects were mainly female (90%) and averaged 0.4 CSBMs 
per week at baseline. The primary efficacy endpoint, change from baseline in spontaneous 
bowel movements (SBMs), showed a dose-dependent increase and highly significant results 
were obtained for the two highest dose levels. In addition, the secondary endpoints of 
effects on SBM and CSBM frequencies were also dose dependent and statistically significant. 
Bloating and straining, important constipation symptoms, also decreased significantly 
during A3309 treatment. The effect of A3309 was rapid and a significantly higher proportion 
of the A3309-treated patients had a CSBM within 24 hours of the first administration. The 
beneficial effects were maintained over the eight-week trial period.  
Abdominal pain and diarrhea once again appeared to be the most common side effects with 
A3309 treatment. These events were observed in 10%, 11%, and 25% and 8%, 11%, and 17%, 
respectively, in the A3309 5 mg, 10 mg, and 15 mg dose groups, compared with only 0% and 
4% in placebo-treated subjects. A similar adverse event profile was recently noted with use 
of chenodeoxycholic acid in healthy volunteers and female subjects with constipation-
predominant IBS (Odynsi-Shiyanbade et al., 2010; Rao A.S. et al., 2010). These observations 
leave the tolerability of choleretic agent an open-ended question at this time. Increased C4 
and reduced LDL cholesterol suggested increased BA synthesis due to inhibition of ileal BA 
transport. As previously discussed, the long-term effects of this therapeutic approach on fat-
soluble vitamin absorption remains to be established. 
5.3 Na-H exchange inhibitors 
5.3.1 RDX-5791 
RDX5791 is a unique, minimally systemic, small molecule NHE3 inhibitor in clinical 
development for the treatment of CIC. Unlike secretagogues that induce active Cl secretion, 
RDX5791 inhibits the intestinal Na-H antiport protein (NHE3) that plays a key role in the 
uptake of sodium and thus water from the intestinal lumen. The most attractive feature of 
the drug’s mechanism is the fact the NHE3 transporter accounts for the principal 
mechanism of Na and water absorption in humans from duodenum to left colon. Unlike 
linaclotide, the actions of which may be restricted to the duodenum, RDX5791 may exert its 
effects along the GI tract. This would theoretically allow for more gradual hydration of 
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stool, and less of a tendency for diarrhea as the dose is increased. The effects of RDX5791 on 
stool consistency and transit time have been demonstrated in animal models  (Spencer et al., 
2011). RDX5791 has been demonstrated to be anti-nocioceptive in an animal model of 
visceral hypersensitivity (Eutamene et al., 2011). Pharmacokinetic trials have been 
completed, and proof-of-concept studies are currently underway in patients with IBS-c. 
6. Related indications  
6.1 Constipation-predominant irritable bowel syndrome 
Drugs that are effective in CIC also appear to be effective in patients with irritable bowel 
syndrome with constipation (IBS-c). The dual effect on CIC and IBS-c appears to apply to most 
prokinetic agents and secretagogues. The distinction between CIC and IBS-c patients may be 
difficult in practice, and it is likely many patients are cross-included in their respective clinical 
trials. Patients typically qualify for IBS-c trials by fulfilling Rome Criteria for IBS-c and 
demonstrating of minimal level of abdominal pain on pre-randomization screening diaries, at 
least 3 out of a possible 10 on a numerical rating scale (Chey et al., 2011b). This practice was 
recently codified in the FDA IBS draft guidance (U.S. Food and Drug Administration, 2010b). 
However, while there have been minimum pain requirements to enter IBS-c trials, there have 
been no maximums that would exclude patients from CIC trials. In fact, it is recognized that a 
number of patients enter CIC trials reporting baseline pain that exceeds the IBS-c minimum 
(Lembo et al., 2010b). A retrospective analysis of Phase 3 CIC data demonstrated that CIC 
patients with a pain score ≥ 3 (on a scale of 10) were as likely to respond to linaclotide as the 
overall study population (Lembo et al, 2011). Interestingly, patients entering a recent 
multicenter IBS-c trial with linaclotide demonstrated more severe constipation than those 
entering CIC trials with the same compound (Johnston et al., 2010). 
The mechanism of pain relief in IBS-c most likely relates to decompression of colonic 
distention, although reduction of visceral hypersensitivity has been suggested using animal 
models (Eutamene et al., 2009). The mechanism of this anti-nocioceptive effect is uncertain, 
since the phenomenon also appears to apply broadly across a variety of promotility agents 
that could have utility in CIC and IBS-c (Eutamene et al., 2011, Greenwood-van Meerveld et 
al., 2006). It has been suggested that stimulation of intracellular c-GMP is responsible for the 
pain reductions with linaclotide use (Eutamene et al., 2009). However, the mechanism of this 
effect remains uncertain, since linaclotide is non-absorbed and appears to be released and 
degraded principally in the duodenum (Kessler et al., 2008), while has been presumed that 
IBS pain originates in the lower GI tract. 
6.2 Opioid-induced constipation 
A number of peripherally acting -opiate antagonists are currently being investigated for 
the treatment of opioid-induced constipation (OIC). These drugs are designed not to 
penetrate or cross the blood brain barrier or adversely impact the efficacy of concomitant 
analgesic therapy. Methylnaltrexone bromide (Relistor®) has been approved for the 
treatment of opiate-induced constipation in patients with advanced illness (Thomas et al., 
2008). The drug is administered subcutaneously and appears to have onset of effect within 
four hours. Oral bioavailability has been a challenge, although a new formulation has 
recently entered Phase 3 trials.  
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Alvimopan is an orally administered peripherally-acting -opioid antagonist approved for 
the treatment of postoperative ileus (Delaney et al., 2008). In one controlled study in 522 
patients on opioids for chronic non-cancer pain, alvimopan in doses of 0.5 mg BID to 2 mg 
BID was superior to placebo in inducing spontaneous bowel movements and reducing 
constipation-associated symptoms without antagonism of opioid analgesia (Jansen J.P. et al., 
2011; Paulson et al., 2005; Webster et al., 2008), although one of the two pivotal trial failed to 
meet statistical significance (Irving et al., 2011). This could have resulted from loss of 
statistical power due to use of SBM rather than CSBM as a primary endpoint, and a placebo 
response exceeding 50%. Development of alvimopan for OIC was discontinued in 2008 
because of a numeric imbalance in myocardial infarction, neoplasm, and bone fracture 
adverse events that appeared in a long-term safety study. 
Several other peripherally-acting -opioid antagonists are currently in development for OIC, 
including TD-1211, NKTR-118, and ALKS-37. One of the challenges will be the development 
of combination drugs that permit co-administration of opioid with opioid antagonists as a 
means to prevent constipation from occurring. It is worth noting that opioid antagonists are 
not expected to cause an increase in the frequency of bowel movements in healthy 
volunteers or patients with constipation associated with other causes rather than opioid. In 
contrast, prokinetic agents are likely to improve constipation associated with opioid usage. 
Lubiprostone and prucalopride are also being studies for the treatment of opioid-induced 
constipation. 
7. Conclusions  
Prokinetic agents and secretagogues in development will most likely assume a position on 
formularies with other constipation therapies, including prucalopride and lubiprostone, and 
OTC agents. Based on current data, it is unlikely that one agent or class of compounds will 
suffice for most patients. The challenge will be to integrate different mechanisms into 
treatment algorithms that optimize safety, cost-effectiveness and therapeutic response. This 
information will be established in future therapeutic trials.  
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